Valence 로고
인기
로그인

관심목록에 추가

Phathom Pharmaceuticals I...

NasdaqGS: PHAT · 실시간 가격 · USD
9.65
+0.40 (4.32%)
종가 기준: Aug 20, 2026, 3:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

Phathom Pharmaceuticals Inc.(PHAT) 주가, 분석 및 데이터

4.32%
매수호가6.84
시가총액709.91M
매출 (ttm)239.66M
순이익 (ttm)-99.07M
0.50
-1.25
n/a
7.91
P/B (ttm)-2.04
P/S (ttm)2.96
실적 발표일Jul 30, 2026
매도호가12.28
거래량86,169
평균 거래량 (20일)1,321,293
시가9.42
전일 종가9.25
일중 범위9.42 - 9.70
52주 범위8.21 - 18.31
애널리스트Strong Buy
목표주가21.5 (122.80%)
배당n/a
배당락일n/a

PHAT 소개

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacte...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Oct 25, 2019
직원 수 371
상장 거래소 NasdaqGS
티커 PHAT
웹사이트 https://www.phathompharma.com
전체 기업 정보

재무 실적

2025년 Phathom Pharmaceuticals의 매출은 175.11M로, 전년 55.25M 대비 216.93% 증가했습니다. 순이익은 -221.25M로, -33.82% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 10명의 투자의견을 종합하면 PHAT 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 21.5로, 최근 주가 대비 122.8% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Phathom Pharmaceuticals가 Apr 30, 2026에 분기 실적을 발표했습니다:
  • 매출 $74.27M 예상치 하회 $0, 및 88.02% 전년 대비 성장.
  • EPS -0.18 예상치 상회 0.01, 및 83.18% 전년 대비 성장.

    • 다음 실적 발표

    Phathom Pharmaceuticals Inc.의 실적 발표 예정일은 Jul 30, 2026, 장 시작 전입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    5일 전 · Simply Wall St.

    Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

    The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a m...

    news image

    3주 전 · Stocktwits

    PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?

    Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.

    news image

    3주 전 · MarketBeat

    Phathom Pharmaceuticals Q2 Earnings Call Highlights

    Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first ...

    news image

    3주 전 · GuruFocus.com

    Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ...

    Phathom Pharmaceuticals Inc (PHAT) achieves milestone profitability and strong revenue growth, but faces physician friction in the prior authorization process for Voquezna.

    news image

    3주 전 · Zacks

    Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

    Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

    2 페이지 중 1